课题基金 / 基金详情

Immunogenicity and HLA restriction of kinase mutations in colorectal adenoma and carcinoma patients

Immunogenicity and HLA restriction of kinase mutations in colorectal adenoma and carcinoma patients
结直肠腺瘤和癌患者激酶突变的免疫原性和 HLA 限制
批准号:
183532
负责人:
Holt Rob
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2009
资助国家:
加拿大
项目状态:
已结题
起止时间:
2009-03-01 至 2010-03-01

项目摘要

项目成果

Holt Rob的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In Canada, colorectal cancer is the fourth most prevalent cancer and the second leading cause of cancer death. New approaches to colorectal cancer control are needed. Over 100 years of research have shown that the immune system can and does prevent cance
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lentiviral infusion as a universal approach for genetically modified immune effector cell therapies.
  • 批准号:
    435855
  • 项目类别:
    Operating Grants
  • 资助金额:
    $46.81万
  • 财政年份:
    2020
  • 负责人:
    Holt Rob
  • 依托单位:
Engineering T cells to overcome an immunosuppressive solid tumour microenvironment
  • 批准号:
    369095
  • 项目类别:
    Operating Grants
  • 资助金额:
    $10.93万
  • 财政年份:
    2017
  • 负责人:
    Holt Rob
  • 依托单位:
Characterizing the human T-cell receptor repertoire by massively parallel sequencing
Linking Infectious Agents to Cancer: A Metagenomics Approach
海外基金